Disc Medicine, Inc.(IRON)

Biotechnology · Watertown, MA

$62.72-0.61 (-0.97%)

Delayed quote: Oct 6, 2026, 10:45 AM EDT

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T14:47:25.261Z.

Stored calculation inputs

Calculation as of: 2026-10-06T14:47:25.261Z.

Quote observation: 2026-10-06T14:45:12.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 2,407,865,880
Total debt · period ending 2026-06-30: 60,862,000
Cash · period ending 2026-06-30: 98,676,000
TTM operating EBITDA · period ending 2026-06-30: -268,910,000

FMP input reference: 76fc2c3b696fe1037033af5d10d354cd3b8573abd6cfebee9ff2ae185940ee40

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

IRON EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

IRON Competitors' EV/EBITDA Ratio

IRON

Disc Medicine, Inc.

Current

Market Cap

$2.41B

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CLOV

Clover Health Investments, Corp.

vs IRON

Market Cap

$2.43B

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ALMR

Alamar Biosciences, Inc.

vs IRON

Market Cap

$2.38B

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LQDA

Liquidia Corporation

vs IRON

Market Cap

$2.37B

EV/EBITDA Ratio

12.98x

TTM Avg

113.41x

3Y Avg

113.41x

5Y Avg

113.41x

ADMA

ADMA Biologics, Inc.

vs IRON

Market Cap

$2.34B

EV/EBITDA Ratio

10.65x

TTM Avg

16.44x

3Y Avg

40.11x

5Y Avg

40.11x

RXRX

Recursion Pharmaceuticals, Inc.

vs IRON

Market Cap

$2.33B

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NRIX

Nurix Therapeutics, Inc.

vs IRON

Market Cap

$2.30B

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HRMY

Harmony Biosciences Holdings, Inc.

vs IRON

Market Cap

$2.27B

EV/EBITDA Ratio

7.31x

TTM Avg

6.56x

3Y Avg

7.54x

5Y Avg

13.22x

MRVI

Maravai LifeSciences Holdings, Inc.

vs IRON

Market Cap

$2.24B

EV/EBITDA Ratio

15.48x

TTM Avg

9.40x

3Y Avg

61.74x

5Y Avg

31.90x

NAMS

NewAmsterdam Pharma Company N.V.

vs IRON

Market Cap

$2.58B

EV/EBITDA Ratio

N/A

TTM Avg

3.68x

3Y Avg

3.68x

5Y Avg

3.68x

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Disc Medicine, Inc. (IRON)	$2.41B	N/A	N/A	N/A	N/A
Clover Health Investments, Corp. (CLOV)vs ›	$2.43B	N/A	N/A	N/A	N/A
Alamar Biosciences, Inc. (ALMR)vs ›	$2.38B	N/A	N/A	N/A	N/A
Liquidia Corporation (LQDA)vs ›	$2.37B	12.98x	113.41x	113.41x	113.41x
ADMA Biologics, Inc. (ADMA)vs ›	$2.34B	10.65x	16.44x	40.11x	40.11x
Recursion Pharmaceuticals, Inc. (RXRX)vs ›	$2.33B	N/A	N/A	N/A	N/A
Nurix Therapeutics, Inc. (NRIX)vs ›	$2.30B	N/A	N/A	N/A	N/A
Harmony Biosciences Holdings, Inc. (HRMY)vs ›	$2.27B	7.31x	6.56x	7.54x	13.22x
Maravai LifeSciences Holdings, Inc. (MRVI)vs ›	$2.24B	15.48x	9.40x	61.74x	31.90x
NewAmsterdam Pharma Company N.V. (NAMS)vs ›	$2.58B	N/A	3.68x	3.68x	3.68x

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics